Literature DB >> 20688025

Deferasirox induced liver injury in haemochromatosis.

Naeem Aslam1, Parveen Mettu, Luis S Marsano-Obando, Anthony Martin.   

Abstract

Durg-induced liver injury is a common side-effect of many medicines. It is particularly problem when the original condition under treatment is already causing liver damage. This report describes the hepatotoxicity induced by Deferasirox in a patient with haemochromatosis with a discussion of possible pathogenetic mechanism.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20688025     DOI： 04.2010/JCPSP.551553

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN： 1022-386X            Impact factor:   0.711


  6 in total

1.  Significant Hyperbilirubinemia and Acute Hepatocellular Jaundice in a Pediatric Patient Receiving Deferasirox: A Case Report.

Authors:  Elizabeth A Feldman; Christopher D Miller; Sarabeth Wojnowicz; Robert Seabury
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jan-Feb

2.  TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.

Authors:  Somayeh Kalanaky; Maryam Hafizi; Sepideh Safari; Kazem Mousavizadeh; Mahboubeh Kabiri; Alireza Farsinejad; Saideh Fakharzadeh; Mohammad Hassan Nazaran
Journal:  Int J Hematol       Date:  2016-02-01       Impact factor: 2.490

3.  Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male.

Authors:  Jacqueline Fraser; Rowena Brook; Tony He; Diana Lewis
Journal:  BMJ Case Rep       Date:  2020-07-09

4.  Acute Liver Failure in a Pediatric Patient with Congenital Dysery-Thropoietic Anemia Type I Treated with Deferasirox.

Authors:  Galina Ling; Vered Pinsk; Inbal Golan-Tripto; Eduard Ling
Journal:  Hematol Rep       Date:  2015-09-23

5.  Pharmacogenetic study of deferasirox, an iron chelating agent.

Authors:  Ji Won Lee; Hyoung Jin Kang; Ji-Yeob Choi; Nam Hee Kim; Mi Kyung Jang; Chang-Woo Yeo; Sang Seop Lee; Hyery Kim; June Dong Park; Kyung Duk Park; Hee Young Shin; Jae-Gook Shin; Hyo Seop Ahn
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

6.  Efficacy and Safety of Deferasirox in Pediatric Patients of Thalassemia at a Tertiary Care Teaching Hospital.

Authors:  Dhaval R Thakor; Chetna K Desai; Jigar D Kapadia; Ram K Dikshit; K M Mehariya
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.